These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11366158)

  • 1. Therapeutic options or antiretroviral anarchy?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jan; 5(1):10-30. PubMed ID: 11366158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic approaches to antiretroviral treatment.
    Havlir DV
    Top HIV Med; 2003; 11(4):145-9. PubMed ID: 12876333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
    Montroni M; Monforte AD
    Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy: still more intuition than data.
    Gilden D
    GMHC Treat Issues; 1999 Jan; 13(1):6-12. PubMed ID: 11366112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When paradigms fall: the demise of "hit hard, hit early".
    Simmons P
    Res Initiat Treat Action; 1999 Dec; 5(5):11-2. PubMed ID: 11366884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV resistance-testing information on web.
    AIDS Treat News; 2000 Feb; (No 337):6. PubMed ID: 11367209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant immunological and virological responses to antiretroviral therapy.
    Schechter M; Tuboi SH
    J Antimicrob Chemother; 2006 Sep; 58(3):506-10. PubMed ID: 16854959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance testing debate: does it make the grade?
    Simmons P
    Res Initiat Treat Action; 1999 Oct; 5(4):9-12. PubMed ID: 11366943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants.
    Van der Linden D; Hainaut M; Goetghebuer T; Haelterman E; Schmitz V; Maes P; Peltier A; Levy J
    Pediatr Infect Dis J; 2007 Apr; 26(4):359-61. PubMed ID: 17414406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple combinations: present and future.
    Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S77-82. PubMed ID: 8595515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance assays in clinical management.
    Martinez-Picado J; D'Aquila R
    AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.